Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
MGF (Mechano Growth Factor)24 residuesYQPPSTNKNTKSQRRKGSTFEERKEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: MGF, IGF-1Ec, Mechano Growth Factor
Five to seven minutes. That's the entire serum half-life of native MGF (Mechano Growth Factor), the 24-amino-acid repair signal your muscles produce after hard training. When the IGF-1 gene splices under mechanical load, it releases this E-domain peptide locally at the site of tissue damage. The job is specific: activate dormant satellite cells so they can start dividing. Animal models from Goldspink's group [1] confirmed satellite cell activation and fiber hypertrophy. But the only rigorous human cell study, Fornaro 2014 [2], found zero effect on human myoblasts. Community users still report DOMS reduction and faster recovery, mostly through precise post-workout intramuscular injection.
Five to seven minutes of biological activity. That's what you get from a single injection of synthetic MGF before enzymes chew it apart. MGF, or Mechano Growth Factor (also called the IGF-1Ec E-domain peptide), is a 24-amino-acid fragment cleaved from the IGF-1 gene's Ec splice variant when muscle fibers stretch, tear, or absorb mechanical load. The mechanism is targeted. MGF is a first-responder repair signal, arriving at the damage site within hours of exercise. Its sole early function is satellite cell activation, pushing these resident muscle stem cells out of their dormant G0 state and into the cell cycle. This happens without triggering differentiation, which comes later through a separate IGF-1Ea pathway. In murine models, Goldspink's team confirmed that MGF expression peaks within 1 to 6 hours of mechanical stimulus [1]. McKoy and colleagues showed that MGF E-peptide activates human muscle progenitor cells and increases fusion potential across different ages [3]. Then there's the catch. Fornaro and colleagues [2] tested synthetic MGF E-peptide at concentrations up to 500 ng/mL on human myoblasts and primary muscle stem cells. The result was no proliferative effect. Mature IGF-1 worked in the same assay; the synthetic E-peptide did not. Community experience tells a different story. Across roughly 50 to 100 Reddit threads and forum discussions, users report reduced delayed-onset muscle soreness and faster session-to-session recovery. The catch: gains don't persist post-cycle, injection timing is impractical, and most experienced users eventually switch to PEG-MGF for its 48 to 72 hour half-life. All current evidence sits in the preclinical and anecdotal space. No human clinical trials have been completed.
Your muscles produce MGF through alternative splicing of the IGF-1 gene. When muscle fibers experience mechanical stress, stretching, or damage, the IGF-1 gene splices to produce the Ec isoform instead of the standard Ea form. The unique 24-amino-acid E-domain peptide (MGF) gets released locally at the injury site. Here's what makes this peptide different from systemic IGF-1. MGF does not signal through the IGF-1 receptor (IGF-1R). It uses a separate, distinct pathway to reach satellite cells, the resident stem cells responsible for muscle regeneration. Once it reaches them, MGF shifts satellite cells from their quiescent G0 state into the G1/S phase of the cell cycle. They start proliferating. They don't differentiate yet. That second step comes later, driven by the IGF-1Ea isoform acting through IGF-1R. This two-phase system matters. MGF expands the pool of myogenic progenitor cells first. IGF-1Ea then tells that expanded pool to differentiate and begin protein synthesis. In cardiac tissue, MGF reduces apoptosis and promotes progenitor cell migration toward ischemic areas [1]. In neural tissue, it activates neural progenitor cells in the hippocampus, promoting neurogenesis in aging mouse brains [4]. The synthetic peptide replicates this E-domain signal, but the 5 to 7 minute half-life means the delivery window is extremely narrow.
Animal and in-vitro models support satellite cell activation and fiber hypertrophy via the MGF E-domain. However, the most rigorous human cell study (Fornaro et al. 2014)[2] found zero proliferative effect of synthetic MGF E-peptide on human myoblasts or primary muscle stem cells at concentrations up to 500 ng/mL. No human clinical trials have been completed. Human efficacy is unproven.
Fornaro M et al. 2014, Am J Physiol Endocrinol Metab (PMID 24253050): negative: synthetic MGF E-peptide had no effect on human myoblasts or primary muscle stem cells; mature IGF-1 did show effect.
No human RCTs. Only rigorous human cell study was negative. Most positive evidence from murine models or transfected cDNA constructs, not exogenous synthetic peptide. Half-life of ~5–7 min makes in-vivo delivery poorly controlled.
Mixed. Cautiously positive for DOMS reduction and recovery. Many users report gains do not persist post-cycle. Practical issues with 5–7 min half-life drive most experienced users to PEG-MGF instead.
Animal science suggested satellite cell activation; the most rigorous human cell study found no effect. Community reports modest recovery benefits, but no confirmed human mechanism exists to explain them. Science-only evidence is weak and partially negative; community use continues based on animal data extrapolation.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 100mcg | Daily |
| Moderate | 200mcg | Daily |
| Aggressive | 300mcg | Daily |
The 5 to 7 minute half-life changes everything about how you use this peptide. You can't bring it home from the gym. You inject within minutes of your last set, or you're wasting product. Reconstitution math for a 2 mg vial with 1 mL bacteriostatic water: each 0.05 mL (5 units on a U-100 insulin syringe) delivers 100 mcg. For 200 mcg, draw 10 units. For 300 mcg, draw 15 units. For a 5 mg vial with 1 mL BAC water: each 0.02 mL (2 units) delivers 100 mcg. Draw 4 units for 200 mcg, 6 units for 300 mcg. The non-obvious thing most beginners miss: subcutaneous abdominal injection defeats the entire mechanism. MGF is a paracrine signal. It needs to be near the muscle you just trained. SC abdominal delivery leads to systemic enzymatic degradation before any peptide reaches the target tissue. Also, split your dose bilaterally when training paired muscles. One hundred mcg per side for biceps, quads, or pecs. Keep protein intake at or above 1.8 g/kg per day. Satellite cells can't build anything without amino acid substrate.
Cycle 4-6 weeks on, 4 weeks off. Inject immediately post-workout near the target muscle. Due to the extremely short half-life, timing is critical: delays of even 30 minutes reduce effectiveness.
Community protocols cycle 4–6 weeks on / 4 weeks off based on presumed receptor tachyphylaxis within the IGF-1 / satellite cell pathway. No human receptor desensitization data specific to synthetic MGF exists. Cycling also allows IGF-1 axis normalization and reduces theoretical risk from continuous mitogenic signaling.
Or use the universal Peptide Calculator for any peptide.
Expected: Modest DOMS reduction and recovery improvement (anecdotal; no controlled human data)
Monitor: Check blood glucose post-injection in early days; watch for injection site reactions.
Add 1 mL of bacteriostatic water to a 2 mg vial. Direct the stream against the glass wall, not the powder cake. Swirl gently. Never shake.
For a 2 mg vial with 1 mL BAC water: 5 units equals 100 mcg, 10 units equals 200 mcg, 15 units equals 300 mcg. Transport the loaded syringe in an insulated pouch with a cold pack.
Timing starts now.
Within 5 minutes of your final set, inject intramuscularly into the belly of the muscle you just trained. Use a 29 or 30 gauge, 0.5 inch insulin needle. For bilateral muscles (biceps, quads, pecs), split the dose evenly between both sides.
Rotate injection sites within the target muscle across sessions. Inspect each site before injecting for redness, warmth, or signs of infection.
Return the reconstituted vial to the refrigerator (2 to 8 degrees Celsius) immediately upon arriving home. Use within 7 to 10 days.
Check fasting blood glucose the morning after your first few injections. If readings drop below 70 mg/dL, reduce your dose or discontinue.
Standard: 100–300 mcg per injection
MGF functions as a local paracrine signal at sites of mechanical damage. Injection near the trained muscle is necessary for any potential localized effect. Split dose bilaterally for paired muscle groups.
Same dose range but most peptide is degraded systemically before reaching target muscle
Community guides consistently cite SC abdominal injection as the top user mistake. Some users accept this route for convenience despite likely absent localized effect. Mechanistically unsound for native MGF.
MGF drives satellite cell proliferation; IGF-1 LR3 drives differentiation. Running sequentially (not simultaneously) covers both phases of muscle regeneration.
MGF 200 mcg/day IM × 4 weeks post-workout → switch to IGF-1 LR3 50–100 mcg/day × 4 weeks; do not co-administer same day.
BPC-157 addresses connective tissue and systemic healing via nitric oxide pathways; MGF addresses satellite cell activation locally. Complementary for injury recovery stacks.
BPC-157 250 mcg/day SC + MGF 200 mcg IM post-workout × 4 weeks
TB-500 promotes actin dynamics, angiogenesis, and progenitor cell migration; MGF activates muscle satellite cells. Combined for injury recovery protocols.
TB-500 2–5 mg SC 2×/week + MGF 200 mcg IM post-workout daily × 4 weeks
MGF E-domain and IGF-1 LR3 act on overlapping satellite cell receptor pathways. Same-day co-administration may cause receptor competition and reduce the proliferative effect of MGF. Stagger by ≥4–6 hours or run in separate cycles.
MGF carries an independent hypoglycemia risk at higher doses. Combining with exogenous insulin or insulin secretagogues significantly increases hypoglycemia risk through additive glucose-lowering effects.
Do not combinePricing updated 2026-04-09
The biggest concern with MGF isn't a side effect you'll feel. It's what you can't measure. No human clinical trials have ever been completed for synthetic MGF. The total body of human-relevant evidence amounts to one rigorous in-vitro study (Fornaro 2014)[2] and community anecdotes. Long-term human safety data does not exist. You're operating without a safety net. Hypoglycemia is the most medically actionable risk. MGF activates the IGF-1 pathway, which lowers blood glucose. At higher doses (200 to 300 mcg range), users should monitor fasting blood glucose, especially during the first week. Anyone stacking MGF with other IGF-1 pathway peptides, insulin, or sulfonylureas faces compounded risk. If you feel dizzy, sweaty, or confused post-injection, check your blood sugar immediately. That's not "feeling the peptide working." That's hypoglycemia. Injection site reactions are common. Daily intramuscular injections into the same muscle group create localized pain, redness, and swelling. Multiple sites per session (bilateral dosing) increases exposure. Rotate sites within the target area and inspect before each injection for signs of infection, granuloma, or abscess. Water retention and temporary bloating show up in community reports. So does joint pain and stiffness, particularly at higher doses. Fatigue and flu-like symptoms appear in some users, especially early in the cycle. These typically resolve by week 2. MGF promotes cell proliferation. That's the entire point, and it's also the reason it's contraindicated in anyone with active cancer, a history of malignancy, or uncontrolled cell growth of any kind. This applies to all IGF-1 pathway peptides without exception. Pregnancy and breastfeeding are absolute contraindications. Children and adolescents with open growth plates should not use MGF. Anyone with uncontrolled diabetes or known hypersensitivity to IGF-1 or related peptides should avoid it entirely. When to stop: if you experience hypoglycemia, signs of infection at the injection site, worsening joint pain, or no perceived benefit by the end of week 3. Glucocorticoids (prednisone, dexamethasone) may block the growth-promoting effects of MGF. Anticoagulant users should monitor for increased bruising at injection sites.
Verify MGF (Mechano Growth Factor) dosing and safety with a second opinion
Extremely short half-life (~5–7 min) makes MGF highly susceptible to degradation during manufacturing, shipping, and storage. No standardized regulatory testing applies to research-grade synthetic peptides. Fornaro 2014 (PMID 24253050) raised the possibility that some commercial batches may be inactive: possibly due to incorrect sequence or pre-delivery degradation. Black-market adulteration documented in WADA/anti-doping mass spectrometry literature.
| Test | When | Target |
|---|---|---|
| Fasting blood glucose | Baseline before starting; recheck at day 7 and week 4 | 70–100 mg/dL fasting |
| Injection site inspection | Before each injection session | — |
| Serum IGF-1 | Optional: baseline and end of 4-week cycle, especially if stacking with IGF-1 LR3 | Age-adjusted normal range (typically 115–307 ng/mL for adults) |
MGF carries a hypoglycemia risk at higher doses via IGF-1 pathway activation; additive risk if stacking with other IGF-1 pathway peptides.
Daily IM injections risk infection, granuloma formation, or abscess: particularly with multiple injection sites per session.
MGF activates IGF-1 pathway; combined use with IGF-1 LR3 can compound pathway stimulation; baseline helps assess net exposure.
Initial adaptation period. Injection site soreness is common early on. No measurable muscle changes expected. Users may notice mild post-workout soreness reduction if injection timing is correct.
Anecdotal reports of improved recovery between sessions and reduced delayed-onset muscle soreness (DOMS). No clinical data supports specific timelines. Effects are highly dependent on injection site and timing.
End of typical cycle. Some users report improved training capacity and recovery. Any observed effects are anecdotal: no controlled human trials exist to validate timelines. Begin taper or transition to off-cycle period.
Allow receptor sensitivity to normalize. Maintain training volume. Some users stack with BPC-157 or TB-500 during the off-cycle for continued recovery support.
Days 1 through 7, Injection Site Adaptation: Don't expect anything measurable this first week. Your body is adapting to the injection protocol, not building muscle. Mild soreness at the injection site is normal; so is light fatigue. Science has no human timeline data to offer here. Some community users report reduced post-workout fatigue by day 4 or 5, but set your expectations low. Weeks 2 through 3, Recovery Improvement Window: This is where community reports start getting interesting. Users who nail the timing (within 5 minutes post-training, IM into the target muscle) describe noticeable DOMS reduction and faster session-to-session recovery. Animal models show peak satellite cell activation within 1 to 6 hours of mechanical stimulus, which lines up with the theoretical window. But "interesting anecdotes" and "proven human endpoints" are very different things. Week 4, Peak Cycle Effects: End of a standard cycle. Some users report improved training capacity and a mild fullness in trained muscles. Multiple EliteFitness and Reddit threads flag an honest warning: the gains are not retained post-cycle. No human biomarker data exists for synthetic MGF at any timepoint. Weeks 5 through 8, Off-Cycle Recovery: Reported benefits fade within 1 to 2 weeks off. This is expected given receptor sensitivity normalization. Many users transition to BPC-157 or TB-500 during the off-cycle for continued recovery support. No human data exists on withdrawal or rebound effects.
No measurable anabolic changes. Adaptation period only.
Mild injection site soreness common. Some users report reduced post-workout fatigue.
No human clinical timeline data. Animal models show peak satellite cell activation 1–6 hours post-stimulus.
Anecdotal DOMS reduction and faster session-to-session recovery. Effect highly dependent on injection timing accuracy and site specificity.
No human clinical endpoints. No measurable biomarker data for synthetic MGF in humans.
Some users report improved training capacity and mild muscle fullness. Multiple forum threads note gains are NOT retained post-cycle.
Receptor sensitivity normalization. No human withdrawal or rebound data.
Reported benefits fade within 1–2 weeks off. Many users transition to BPC-157 or TB-500 for continued recovery support during the off-cycle.
Source: Estimated ~5-7 minutes; Goldspink G, Endocrinology 2010 (PMID 20130113)
Loading the interactive decay curve.
MGF (Mechano Growth Factor) holds a "research-only" regulatory status. It is not approved by the FDA for any therapeutic use in humans. No human clinical trials have been completed, and no new drug application has been filed. MGF is available through research chemical suppliers as a lyophilized peptide sold for "in vitro research use only" or "laboratory use only." It is not a dietary supplement, and no compounding pharmacy formulation exists under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. For athletes: MGF falls under the WADA prohibited list as an IGF-1 splice variant. It is banned in-competition and out-of-competition under section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Testing via mass spectrometry is documented in anti-doping literature. Quality control is a real concern. The research peptide market is unregulated, and batch variability is high. Fornaro 2014 raised the possibility that some commercial batches may be inactive due to incorrect sequence or degradation before delivery. Always request third-party COA with HPLC purity and mass spectrometry confirmation. This content is for informational and research purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any research peptide.
Peptide Schedule Research TeamReviewed Apr 20266 Citations
